Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, Collin P, Green PHR, Crowe SE, Tsuji W, Butz E, Cerf-Bensussan N, Macintyre E, Parnes JR, Leon F, Hermine O, Mulder CJ; RCD-II Study Group Investigators. Cellier C, et al. Among authors: van gils t. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):960-970. doi: 10.1016/S2468-1253(19)30265-1. Epub 2019 Sep 4. Lancet Gastroenterol Hepatol. 2019. PMID: 31494097 Clinical Trial.
Mechanisms and management of refractory coeliac disease.
van Gils T, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ. van Gils T, et al. Among authors: van wanrooij rl. Nat Rev Gastroenterol Hepatol. 2015 Oct;12(10):572-9. doi: 10.1038/nrgastro.2015.155. Epub 2015 Sep 8. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26347156 Review.
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°. Cheminant M, et al. Among authors: van gils t. Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17. Gut. 2019. PMID: 30448772
Gamma-Delta T Lymphocytes in the Diagnostic Approach of Coeliac Disease.
Nijeboer P, van Gils T, Reijm M, Ooijevaar R, Lissenberg-Witte BI, Bontkes HJ, Mulder CJJ, Bouma G. Nijeboer P, et al. Among authors: van gils t. J Clin Gastroenterol. 2019 May/Jun;53(5):e208-e213. doi: 10.1097/MCG.0000000000001060. J Clin Gastroenterol. 2019. PMID: 29782465
[Coeliac disease and dentistry].
van Gils T, de Boer NK, Bouma G. van Gils T, et al. Ned Tijdschr Tandheelkd. 2015 Sep;122(9):443-8. doi: 10.5177/ntvt.2015.09.15145. Ned Tijdschr Tandheelkd. 2015. PMID: 26397103 Review. Dutch.
Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor.
Nijeboer P, van Wanrooij R, van Gils T, Wierdsma NJ, Tack GJ, Witte BI, Bontkes HJ, Visser O, Mulder C, Bouma G. Nijeboer P, et al. Among authors: van wanrooij r, van gils t. United European Gastroenterol J. 2017 Mar;5(2):208-217. doi: 10.1177/2050640616646529. Epub 2016 Jun 23. United European Gastroenterol J. 2017. PMID: 28344788 Free PMC article.
21 results